General Information of Disease (ID: DISSVBRR)

Disease Name Ehlers-Danlos syndrome
Synonyms
ED syndrome; Danlos disease; skin elastic; Ehlers Danlos Syndrome; Ehlers Danlos syndrome; Ehler Danlos Syndrome; Ehlers Danlos Disease; Hereditary collagen dysplasia; EDS; Disease, Ehlers-Danlos; Ehlers-Danlos Disease; Fibrodysplasia elastica generalisata; elastic skin; Meekeren-Ehlers-Danlos syndrome; Disease, Ehlers Danlos; danlos ehlers syndrome; Danlos Disease, Ehlers; Dystrophia mesodermalis congenita; Syndrome, Ehlers-Danlos; Ehlers-Danlos syndromes
Disease Class LD28: Connective tissue syndrome
Definition
The EhlersDanlos syndromes (EDS) are a clinically and genetically heterogeneous group of heritable connective tissue disorders (HCTDs) characterized by joint hypermobility, skin hyperextensibility, and tissue fragility.
Disease Hierarchy
DIS6SVEE: Syndromic disease
DISYKSRF: Genetic disease
DIS7GG31: Developmental defect during embryogenesis
DISSVBRR: Ehlers-Danlos syndrome
ICD Code
ICD-11
ICD-11: LD28.1
Expand ICD-11
'LD28.1
Expand ICD-10
'M35; 'M35.7; 'Q79.6
Disease Identifiers
MONDO ID
MONDO_0020066
MESH ID
D004535
UMLS CUI
C0013720
MedGen ID
41720
Orphanet ID
98249
SNOMED CT ID
398114001

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 1 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
ACER-002 DMVW5LN Phase 3 NA [1]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)
This Disease Is Related to 11 DTT Molecule(s)
Gene Name DTT ID Evidence Level Mode of Inheritance REF
PLOD1 TTEKJP3 moderate Genetic Variation [2]
ADAMTS4 TTYG6BU Strong Altered Expression [3]
CIT TT3BKTU Strong Biomarker [4]
COL1A2 TTUABC1 Strong Genetic Variation [5]
CYP21A2 TTP4GLG Strong Genetic Variation [6]
DMPK TTZQTY2 Strong Biomarker [7]
IL1R2 TT51DEV Strong Biomarker [8]
NPPC TTRK0B9 Strong Biomarker [8]
NPR2 TTNB7IF Strong Altered Expression [8]
PLOD2 TT8MEUD Strong Altered Expression [9]
HCRT TTU5HJP Definitive Altered Expression [10]
------------------------------------------------------------------------------------
⏷ Show the Full List of 11 DTT(s)
This Disease Is Related to 1 DTP Molecule(s)
Gene Name DTP ID Evidence Level Mode of Inheritance REF
SLC39A13 DTOTKBS moderate Biomarker [11]
------------------------------------------------------------------------------------
This Disease Is Related to 26 DOT Molecule(s)
Gene Name DOT ID Evidence Level Mode of Inheritance REF
ADAMTSL2 OTAXNV2U Limited Autosomal dominant [12]
ATP6V0D2 OTMOZJO0 Limited Autosomal recessive [12]
ADAMTS2 OTTK22NO Strong Genetic Variation [13]
AEBP1 OTBI1RZ6 Strong Biomarker [14]
ATP6V0A2 OTJBDX0Y Strong Biomarker [15]
B3GALT4 OTLKSMQE Strong Genetic Variation [16]
B3GALT6 OTF4HBAT Strong Biomarker [17]
C1R OTA0ZNIU Strong Genetic Variation [18]
CENPJ OTZCQZN5 Strong Genetic Variation [19]
CHST14 OT3FLH7U Strong Biomarker [20]
COL12A1 OTHLTV53 Strong Genetic Variation [21]
COL1A1 OTI31178 Strong Genetic Variation [22]
COL3A1 OTT1EMLM Strong Genetic Variation [22]
COL5A1 OT24078H Strong Genetic Variation [23]
COL5A2 OT5VOSQE Strong Genetic Variation [24]
COL5A3 OTCGC4DM Strong Biomarker [25]
DSE OTQ108VJ Strong Genetic Variation [26]
EDA OTAKS5WS Strong Biomarker [27]
FAM20B OTOA0UYT Strong Genetic Variation [16]
FKBP14 OT55W5WC Strong Genetic Variation [28]
MED18 OT6M6CQ8 Strong Genetic Variation [29]
PDSS2 OTEOQBMX Strong Biomarker [30]
REM1 OTUXL0HC Strong Genetic Variation [31]
SEMA6A OTDQ7QAW Strong Genetic Variation [32]
SP140 OTQZHFMT Strong Biomarker [8]
TAB2 OTPZK76F Strong Genetic Variation [33]
------------------------------------------------------------------------------------
⏷ Show the Full List of 26 DOT(s)

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Arterial fragility in kyphoscoliotic Ehlers-Danlos syndrome.BMJ Case Rep. 2018 Jul 6;2018:bcr2018224423. doi: 10.1136/bcr-2018-224423.
3 Expanding the clinical and mutational spectrum of the Ehlers-Danlos syndrome, dermatosparaxis type.Genet Med. 2016 Sep;18(9):882-91. doi: 10.1038/gim.2015.188. Epub 2016 Jan 14.
4 Excessive daytime sleepiness may be associated with caudate denervation in Parkinson disease.J Neurol Sci. 2018 Apr 15;387:220-227. doi: 10.1016/j.jns.2018.02.032. Epub 2018 Feb 21.
5 COL1-related overlap disorder: A novel connective tissue disorder incorporating the osteogenesis imperfecta/Ehlers-Danlos syndrome overlap.Clin Genet. 2020 Mar;97(3):396-406. doi: 10.1111/cge.13683. Epub 2019 Dec 12.
6 Tenascin-X, Congenital Adrenal Hyperplasia, and the CAH-X Syndrome.Horm Res Paediatr. 2018;89(5):352-361. doi: 10.1159/000481911. Epub 2018 May 7.
7 Daytime sleepiness and myotonic dystrophy.Curr Neurol Neurosci Rep. 2013 Apr;13(4):340. doi: 10.1007/s11910-013-0340-9.
8 Whole Genome DNA Methylation Analysis of Obstructive Sleep Apnea: IL1R2, NPR2, AR, SP140 Methylation and Clinical Phenotype.Sleep. 2016 Apr 1;39(4):743-55. doi: 10.5665/sleep.5620.
9 Decreased expression of lysyl hydroxylase 2 (LH2) in skin fibroblasts from three Ehlers-Danlos patients does not result from mutations in either the coding or proximal promoter region of the LH2 gene.Mol Genet Metab. 2004 Dec;83(4):312-21. doi: 10.1016/j.ymgme.2004.07.013.
10 Orexin/hypocretin levels in the cerebrospinal fluid and characteristics of patients with myotonic dystrophy type 1 with excessive daytime sleepiness.Neuropsychiatr Dis Treat. 2018 Feb 8;14:451-457. doi: 10.2147/NDT.S158651. eCollection 2018.
11 Morphometric analysis of thoracic aorta in Slc39a13/Zip13-KO mice.Cell Tissue Res. 2019 Apr;376(1):137-141. doi: 10.1007/s00441-018-2977-9. Epub 2019 Jan 4.
12 Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
13 A homozygous ADAMTS2 nonsense mutation in a Doberman Pinscher dog with Ehlers Danlos syndrome and extreme skin fragility.Anim Genet. 2019 Oct;50(5):543-545. doi: 10.1111/age.12825. Epub 2019 Jul 11.
14 Bi-allelic AEBP1 mutations in two patients with Ehlers-Danlos syndrome.Hum Mol Genet. 2019 Jun 1;28(11):1853-1864. doi: 10.1093/hmg/ddz024.
15 Autosomal recessive cutis laxa type 2A (ARCL2A) mimicking Ehlers-Danlos syndrome by its dermatological manifestations: report of three affected patients.Am J Med Genet A. 2014 May;164A(5):1245-53. doi: 10.1002/ajmg.a.36411. Epub 2014 Jan 29.
16 Xylose phosphorylation functions as a molecular switch to regulate proteoglycan biosynthesis.Proc Natl Acad Sci U S A. 2014 Nov 4;111(44):15723-8. doi: 10.1073/pnas.1417993111. Epub 2014 Oct 20.
17 A B3GALT6 variant in patient originally described as Al-Gazali syndrome and implicating the endoplasmic reticulum quality control in the mechanism of some 3GalT6-pathy mutations.Clin Genet. 2018 Jun;93(6):1148-1158. doi: 10.1111/cge.13236. Epub 2018 Mar 15.
18 A Chinese family with periodontal Ehlers-Danlos syndrome associated with missense mutation in the C1R gene.J Clin Periodontol. 2018 Nov;45(11):1311-1318. doi: 10.1111/jcpe.12988.
19 Women with symptoms of sleep-disordered breathing are less likely to be diagnosed and treated for sleep apnea than men.Sleep Med. 2017 Jul;35:17-22. doi: 10.1016/j.sleep.2017.02.032. Epub 2017 Apr 23.
20 Vascular abnormalities in the placenta of Chst14-/- fetuses: implications in the pathophysiology of perinatal lethality of the murine model and vascular lesions in human CHST14/D4ST1 deficiency.Glycobiology. 2018 Feb 1;28(2):80-89. doi: 10.1093/glycob/cwx099.
21 Novel defects in collagen XII and VI expand the mixed myopathy/Ehlers-Danlos syndrome spectrum and lead to variant-specific alterations in the extracellular matrix.Genet Med. 2020 Jan;22(1):112-123. doi: 10.1038/s41436-019-0599-6. Epub 2019 Jul 5.
22 Classical Ehlers-Danlos syndrome with a propensity to arterial events: A new report on a French family with a COL1A1 p.(Arg312Cys) variant.Clin Genet. 2020 Feb;97(2):357-361. doi: 10.1111/cge.13643. Epub 2019 Oct 1.
23 Compound phenotype of osteogenesis imperfecta and Ehlers-Danlos syndrome caused by combined mutations in COL1A1 and COL5A1.Biosci Rep. 2019 Jul 25;39(7):BSR20181409. doi: 10.1042/BSR20181409. Print 2019 Jul 31.
24 A case of Ehlers-Danlos syndrome presenting with widened atrophic scars of forehead, elbow, knee, and pretibial area: A case report.Medicine (Baltimore). 2019 Sep;98(37):e17138. doi: 10.1097/MD.0000000000017138.
25 The pro-alpha3(V) collagen chain. Complete primary structure, expression domains in adult and developing tissues, and comparison to the structures and expression domains of the other types V and XI procollagen chains.J Biol Chem. 2000 Mar 24;275(12):8749-59. doi: 10.1074/jbc.275.12.8749.
26 DSE associated musculocontractural EDS, a milder phenotype or phenotypic variability.Eur J Med Genet. 2020 Apr;63(4):103798. doi: 10.1016/j.ejmg.2019.103798. Epub 2019 Oct 23.
27 Altered fibronectin mRNA splicing in skin fibroblasts from Ehlers-Danlos syndrome patients: in situ hybridization analysis.Cell Biol Int Rep. 1991 Dec;15(12):1195-206. doi: 10.1016/0309-1651(91)90091-v.
28 Primary muscle involvement in a 15-year-old girl with the recurrent homozygous c.362dupC variant in FKBP14.Am J Med Genet A. 2019 Feb;179(2):317-321. doi: 10.1002/ajmg.a.61006. Epub 2018 Dec 18.
29 Targeted next-generation sequencing makes new molecular diagnoses and expands genotype-phenotype relationship in Ehlers-Danlos syndrome.Genet Med. 2016 Nov;18(11):1119-1127. doi: 10.1038/gim.2016.14. Epub 2016 Mar 24.
30 Association between Sleep Disturbances and Daytime Somnolence in Parkinson's Disease.Eur Neurol. 2018;80(5-6):268-276. doi: 10.1159/000496937. Epub 2019 Feb 7.
31 Excessive daytime sleepiness and fatigue in neurological disorders.Sleep Breath. 2020 Jun;24(2):413-424. doi: 10.1007/s11325-019-01921-4. Epub 2019 Aug 23.
32 Kyphoscoliotic type of Ehlers-Danlos Syndrome (EDS VIA) in six Egyptian patients presenting with a homogeneous clinical phenotype.Eur J Pediatr. 2015 Jan;174(1):105-12. doi: 10.1007/s00431-014-2429-9. Epub 2014 Oct 3.
33 A recognizable systemic connective tissue disorder with polyvalvular heart dystrophy and dysmorphism associated with TAB2 mutations. Clin Genet. 2018 Jan;93(1):126-133. doi: 10.1111/cge.13032. Epub 2017 Aug 21.